Incyte-Merck trial failure deals a blow to cancer immunotherapy, but researchers remain hopeful – CNBC
CNBC |
Incyte-Merck trial failure deals a blow to cancer immunotherapy, but researchers remain hopeful
CNBC The future of cancer immunotherapy looks promising, but it suffered a major setback on Friday. Incyte announced that its trial drug epacadostat did not help melanoma patients, and the company is halting the study altogether. Epacadostat was supposed to … Melanoma trial failure deals heavy blow to immunotherapy hopesFinancial Times Incyte stock drops after melanoma therapy drug testing failsThe News Journal Incyte Shares Tumble After Cancer Drug Fails in Trial With Merck’s KeytrudaWall Street Journal Markets Insider –STAT all 201 news articles » |
News@UofT |
Undergraduate students get rare chance to work with groundbreaking genetic engineering technique CRISPR
News@UofT It’s a groundbreaking genetic engineering technique normally reserved for research labs, but this year more than 40 undergraduate students in the Faculty of Arts & Science’s human biology program had a chance to work hands-on with CRISPR, a research … |
Science Daily |
Not just housekeeping: A new way to control protein production in stem cells
Science Daily Postdoc Nina Corsini and other members of Knoblich’s lab discovered that in embryonic stem cells, HTATSF1 is a component of spliceosomes. Its presence means that the machine removes introns from particular RNAs. After this stage of processing, they are … Waking up “sleeping” stem cells in the brain could improve its ability to repair injuryNews-Medical.net Russia-bound for stem cell operationStar Kiwi It’s all about the (stem cell) neighborhoodEurekAlert (press release) The Financial Analyst –The Financial –Facts of Week all 13 news articles » |
FiercePharma |
Medicare to pay hundreds of thousands for CAR–T therapies
BioPharma Dive CAR-T therapies work by taking a patient’s T–cells, engineering them to better combat cancer, and infusing them back into the body. The process is highly complex, highly expensive and, as seen in clinical investigations, highly effective. The approval … US Medicare sets outpatient rate for Yescarta reimbursementPharmaLive (press release) |
FiercePharma |
Medicare to pay hundreds of thousands for CAR–T therapies
BioPharma Dive CAR-T therapies work by taking a patient’s T–cells, engineering them to better combat cancer, and infusing them back into the body. The process is highly complex, highly expensive and, as seen in clinical investigations, highly effective. The approval … US Medicare sets outpatient rate for Yescarta reimbursementPharmaLive (press release) |
Star Kiwi |
Russia-bound for stem cell operation
Star Kiwi Her condition is not yet considered bad enough to qualify for Government funding for disease-modifying drugs. So, Mrs Fisher, husband Kelvin and son Corban are fundraising $100,000 to get her to Moscow, Russia, in August for a stem cell transplant. The … It’s all about the (stem cell) neighborhoodEurekAlert (press release) Stem Cell Market is Trending Worldwide due to Trend’s, Analysis & Forecast 2023The Financial Animal Stem Cell Therapy Market: Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2018–2023Facts of Week |